Ligand Pharmaceuticals Inc.
LGND
Key stats
- Open
- 316.57
- Day high
- 325.89
- Day low
- 310.08
- Previous close
- 316.83
- Volume
- 248.3K
- VWAP
- 319.74
- 52-week high
- 326.63
- 52-week low
- 175.89
- Market cap
- 6.34B
- Shares out
- 20.00M
- Employees
- 47
- Listed
- 1994
About Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
PHARMACEUTICAL PREPARATIONS · SAN DIEGO, CA · ligand.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 93
- Put open interest
- 34
- Put/call
- 0.37
- At-the-money IV
- 43.5%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 270 put | 1.50 | Oct 28, 12:39 PM | 10 | 20 | 62.5% |
| 290 call | 21.90 | Sep 9, 11:57 AM | 5 | 9 | 47.4% |
| 310 call | 14.30 | Nov 12, 3:00 PM | 3 | 11 | 44.8% |
| 330 call | 2.50 | Nov 6, 11:18 AM | 3 | 21 | 44.0% |
| 320 put | 9.50 | Nov 11, 1:58 PM | 3 | 7 | 39.7% |
| 340 call | 2.15 | Nov 12, 1:28 PM | 2 | 3 | 49.3% |
Quarterly results
Massive · Oct 30, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $78.75M | $63.69M | $51.72M | $59.67M |
| Gross profit | $65.89M | $52.38M | $40.35M | $56.67M |
| Operating income | −$15.76M | $8.59M | $17.37M | $13.84M |
| Net income | −$28.48M | $48.51M | −$13.35M | $44.78M |
| Diluted EPS | -1.43 | 2.22 | -0.67 | 2.09 |
| Operating cash flow | −$27.59M | $24.02M | $48.69M | $45.91M |
| Assets | $2.24B | $2.19B | $1.53B | $1.56B |
| Liabilities | $1.28B | $1.22B | $534.78M | $543.42M |
| Equity | $961.76M | $967.52M | $997.32M | $1.02B |
Technicals
Massive · Nov 12, 2026- 50-day average301.33
- 200-day average257.80
- RSI (14 days)55.4
Short interest
Massive · Oct 30, 2026- Oct 30, 20262.46M shares · 10.5 days to cover
- Oct 15, 20262.50M shares · 10.5 days to cover
- Sep 30, 20262.68M shares · 8.7 days to cover
- Sep 15, 20262.63M shares · 13.5 days to cover
Dividends
Massive · Jul 2, 2010- Ex Jul 2, 2010, paid Jul 1, 20100.0763
- Ex Apr 3, 2007, paid Apr 19, 20072.5000
Splits
Massive · Nov 19, 2010- Nov 19, 20101-for-6
Related companies
MassiveNews coverage
No stories about Ligand Pharmaceuticals Inc. right now.